Literature DB >> 6142756

Chronic GM1 ganglioside treatment reduces dopamine cell body degeneration in the substantia nigra after unilateral hemitransection in rat.

G Toffano, G E Savoini, F Moroni, G Lombardi, L Calzà, L F Agnati.   

Abstract

The effect of GM1 ganglioside on the recovery of dopaminergic nigro-striatal neurons was studied in rats after unilateral hemitransection. GM1 treatment partially prevented the decrease of tyrosine hydroxylase (TH) activity caused by hemitransection in the substantia nigra ipsilateral to the lesion. Concomitantly a significant increase of TH-immunoreactivity in the substantia nigra was also detected. In particular, chronic treatment with GM1 prevented the disappearance of TH-positive cell bodies in the substantia nigra and induced the appearance of longer TH-positive dendrites with respect to the saline treatment. These data indicate that GM1 treatment maintains the number of dopaminergic cell bodies in the substantia nigra after hemitransection by protecting against retrograde neuronal degeneration.

Entities:  

Mesh：

Substances：

Year:  1984        PMID： 6142756     DOI： 10.1016/0006-8993(84)90061-1

Source DB:  PubMed          Journal:  Brain Res        ISSN： 0006-8993            Impact factor:   3.252


  10 in total

1.  Enhanced sprouting of retinotectal fibers after early superior colliculus lesions in hamsters treated with gangliosides.

Authors:  B A Sabel; G E Schneider
Journal:  Exp Brain Res       Date:  1988       Impact factor: 1.972

Review 2.  GM1 Ganglioside: Past Studies and Future Potential.

Authors:  Massimo Aureli; Laura Mauri; Maria Grazia Ciampa; Alessandro Prinetti; Gino Toffano; Cynthia Secchieri; Sandro Sonnino
Journal:  Mol Neurobiol       Date:  2015-03-12       Impact factor: 5.590

3.  Incorporation of exogenous ganglioside GM1 into neuroblastoma membranes: inhibition by calcium ion and dependence upon membrane protein.

Authors:  K C Leskawa; R E Erwin; A Leon; G Toffano; E L Hogan
Journal:  Neurochem Res       Date:  1989-06       Impact factor: 3.996

Review 4.  Is ganglioside GM1 effective in the treatment of stroke?

Authors:  S Braune
Journal:  Drugs Aging       Date:  1991-01       Impact factor: 3.923

5.  Dose- and time-dependent hippocampal cholinergic lesions induced by ethylcholine mustard aziridinium ion: effects of nerve growth factor, GM1 ganglioside, and vitamin E.

Authors:  G V Johnson; M Simonato; R S Jope
Journal:  Neurochem Res       Date:  1988-08       Impact factor: 3.996

6.  Gangliosides potentiate in vivo and in vitro effects of nerve growth factor on central cholinergic neurons.

Authors:  A C Cuello; L Garofalo; R L Kenigsberg; D Maysinger
Journal:  Proc Natl Acad Sci U S A       Date:  1989-03       Impact factor: 11.205

Review 7.  Ganglioside function in the development and repair of the nervous system. From basic science to clinical application.

Authors:  S D Skaper; A Leon; G Toffano
Journal:  Mol Neurobiol       Date:  1989       Impact factor: 5.590

8.  GM1 gangliosides stimulate neuronal reorganization and reduce rotational asymmetry after hemitransections of the nigro-striatal pathway.

Authors:  B A Sabel; G L Dunbar; W M Butler; D G Stein
Journal:  Exp Brain Res       Date:  1985       Impact factor: 1.972

Review 9.  Temporal Lobe Necrosis Following Radiotherapy in Nasopharyngeal Carcinoma: New Insight Into the Management.

Authors:  Xin Zhou; Peiyao Liu; Xiaoshen Wang
Journal:  Front Oncol       Date:  2021-01-21       Impact factor: 6.244

10.  A role for gangliosides in astroglial cell differentiation in vitro.

Authors:  L Facci; S D Skaper; M Favaron; A Leon
Journal:  J Cell Biol       Date:  1988-03       Impact factor: 10.539
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.